FAK-mediated activation of ERK for eosinophil migration: a novel mechanism for infection-induced allergic inflammation.
Bacterial and viral infections often induce the exacerbation of allergic diseases. In this study, we investigated the activation of human eosinophils by different microbial products via Toll-like receptors (TLRs). The underlying intracellular mechanism involving activation of extracellular signal-regulated kinase (ERK) and focal adhesion kinase (FAK), an integrin-associated focal adhesion molecule, was also examined. Seven TLR ligands were studied for their abilities in promoting survival, modulating the expression of adhesion molecules and facilitating chemotactic migration of eosinophils. While peptidoglycan (PGN) (TLR2 ligand) showed the most prominent effects, flagellin (TLR5 ligand) and imiquimod R837 (TLR7 ligand) were also effective in activating eosinophils. However, little or no effect was observed for double-stranded polyinosinic-polycytidylic acid (TLR3 ligand), ultra-purified LPS (TLR4 ligand), single-stranded RNA (ssRNA) (TLR8 ligand) and CpG-DNA (TLR9 ligand). Further investigation confirmed that PGN, flagellin and R837 commonly transmitted signals through ERK activation that required prior phosphorylation of tyrosine 925, but not tyrosine 577, on FAK. Moreover, the inhibition of ERK activation by selective inhibitor PD98059 and FAK expression by FAK-specific RNA interference could significantly abolish the stimulatory effects induced by PGN, flagellin and R837. Taken together, our findings indicate the involvement of FAK-dependent activation of ERK1 in TLR-mediated eosinophil stimulation. A potential role of eosinophils was also suggested in exacerbating allergic inflammation in response to microbial infections.
Cheung
Phyllis Fung-Yi
PF
Department of Chemical Pathology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong.
Wong
Chun-Kwok
CK
Ip
Wai-Ki
WK
Lam
Christopher Wai-Kei
CW
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000634:Aminoquinolines / Q000494:pharmacology; D015815:Cell Adhesion Molecules / Q000276:immunology; D002465:Cell Movement / Q000276:immunology*; D002470:Cell Survival / Q000187:drug effects; D004804:Eosinophils / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000276:immunology*; D005408:Flagellin / Q000494:pharmacology; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000235:genetics / Q000276:immunology*; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D000077271:Imiquimod; D007249:Inflammation / Q000276:immunology*; D010457:Peptidoglycan / Q000494:pharmacology; D010766:Phosphorylation / Q000276:immunology; D015398:Signal Transduction / Q000187:drug effects; D051193:Toll-Like Receptors / Q000276:immunology
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D015815:Cell Adhesion Molecules; D010457:Peptidoglycan; D051193:Toll-Like Receptors; D005408:Flagellin; D051416:Focal Adhesion Protein-Tyrosine Kinases; D048049:Extracellular Signal-Regulated MAP Kinases; D000077271:Imiquimod